Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTITUDE-HCM: Ninerafaxstat in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
NCT07023614Phase 2Recruiting
- Sponsor
- Imbria Pharmaceuticals
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Ninerafaxstat 200mg MR BID with Placebo BID (2 arms). Primary endpoint: Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at 12 weeks. Started Oct 2025; status: recruiting.
02
Drugs
ninerafaxstat
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT07023614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07023614.